bullish
EuBiologics (206650 KS): Capacity Expansion Amid Global Supply Shortage to Accelerate Growth
244 Views23 May 2023 18:10
SUMMARY
- Due to the surging cholera cases globally, demand for cholera vaccines for public market continues to grow. According to GAVI, shortage of cholera vaccine is likely to continue through 2025.
- To respond to surging vaccine demand, Eubiologics (206650 KS) plans to increase its production capacity from the current 33M doses per year to a maximum of 90M doses in 2027.
- Eubiologics, in partnership with TechInvention is launching Euvichol-Plus in India. India is among the top cholera-endemic countries, with an estimated incidence rate of 1.64 per 1,000 people.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- EuBiologics (206650 KS): Secular Sectoral Tailwind Is Not The Only Catalyst15 Apr 2024
- EuBiologics (206650 KS): Solid 1H23 Performance; Oral Cholera Vaccine on A Consistent Growth Path09 Sep 2023
- EuBiologics (206650 KS): Capacity Expansion Amid Global Supply Shortage to Accelerate Growth23 May 2023
- EuBiologics (206650 KS): Accelerated Double-Digit Sales Growth In 2022; Strong Demand to Continue22 Feb 2023
- EuBiologics (206650 KS): Base Business Recovery; COVID Vaccine Undergoing Phase 3 Trial18 Mar 2022
- EuBiologics (206650 KS): Cashing on Vaccine Business13 Oct 2021
x